You are on page 1of 12


Saurabh Sharma Sharad Suhane Shashank Srivastava Shreeram Sharma Siddarth Tyagi Shikha Sisodia

.8 million).800 crore(US$ 1.France and US and subsidiaries in US.India.Ireland and France.Introduction: Research and technological oriented pharmaceutical company founded in 1960s headquartered in Mumbai.600 crore(US$ 802.3.Ireland .  14 manufacturing plants in India.UK.  The company has the market capitalization of Rs.7 billion) and an annual turn over of Rs.4.UK.

Wockhardt Group has a strong presence in more than 50% of the therapeutic segments with therapy focused marketing divisions.  Wockhardt is the 4th Indian pharma company to be in the global elite group of 100(Source-Scrip 100. There are more than 200 products in the global market and 71 more products were launched in the FY 2010-11. cough therapy.  In the domestic market. It has a significant presence in pain management. psychotic drugs. vaccines. diabetology. nutrition and super STRILES PRODUCTS ORALS specialty hospitals. NUTRITI ONALS BIOPHAR MACEUT ICLAS .2011 Edition).

  .Atopiclair.Byetta Pharmaceutical and biotechnology major wockhardt limited has forged in-licensing agreement with sinclair pharma for dermatological and dental products eg. Wockhardt has fully ventured into one of the fastest growing pharmaceutical business domains of CRAMS eg.Aloclair The indian dermatological market is worth a whooping 1782 crore.Papulex.

 Wockhardt hospital showed impressive growth this year under the direction of newly appointed M. Core speciality are heart care.bone and joint.laproscopic and urology.   .D. During 2006 Wockhardt completed its largest acquisition to date Pinewood health care to become a major player in the Irish generic market.brain and spine.Zahabiya khorakiwala.

S. Marketing of in-licensed products in INDIA.STRENGHTS  Strong expertise in the area of Recombinant      Biotechnology. . Strong sales force in INDIA. market. Strong ANDA pipeline. Strong presence in the European market & U. USFDA approved manufacturing facilities.

 New molecules under trial.OPPORTUNITIES  Patent expiry of large pool of products. .  Research in the field of herbal medicines.

.5x.WEAKNESS • Nascent presence in the US market (Less than 10% contribution to total revenues) • Highly leveraged balance sheet with D/E ratio more than 1.

• Any expensive acquisitions may increase payback period. with growing competition from companies like Orchid Chemicals and Lupin. restrict expected revenue growth (price erosion more than 95%) specially in cephalosporin segment.THREATS • Pricing pressure in the US. • Increasing competition in the European generic market with the growing presence of frontline Indian pharma companies including Ranbaxy and Reddys. • Regulatory issues may delay approvals. • There is a risk of domestic currency appreciation as the company derives major revenue from international operations (1 to 3% impact on operating profits for every one rupee appreciation) .

 Focused on lifestyle disease segment in domestic market .  • The company’s revenue from the US market will grow at a high rate due to low penetration and strong product pipeline.• Marketing and manufacturing synergies generated from various acquisitions in the European market will help the company improve net profit margin in excess of 15%.  • Advantage of the low genericisation in these markets.

 • The company’s expertise in biotechnology segment will give it a huge opportunity of introducing biogenerics in regulated markets. .  • The company may strike another lucrative acquisition deal because it has huge cash available with it. • The domestic business will be above industry growth due to significant presence in the chronic therapy areas.